Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of 611 in adolescents with moderate-to-severe atopic dermatitis
CTR20252150Phase 3Active
- Sponsor
- 3S Guojian Pharmaceutical
- Start
- Aug 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of SSGJ-611 in atopic dermatitis (AD), sponsored by 3S Guojian Pharmaceutical. Started Aug 2025; status: active.
02
Drugs
SSGJ-611
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on CTR20252150.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20252150.